11 September 2007
Cognos Clinical Trial Enrollment Forecasting Blueprint offers flexible patient enrollment modeling and analytics, enabling managers to track enrollment progress, success of costly studies
2007 CLINICAL PERFORMANCE METRICS SUMMIT, Philadelphia, PA September 11, 2007– Cognos (NASDAQ: COGN; TSX: CSN), the world leader in business intelligence and performance management solutions, continues to extend its pharmaceutical market leadership, announcing today the launch of a new performance solution designed to help pharmaceutical companies better anticipate and manage patient enrollment requirements to ensure clinical trials successfully comply with FDA requirements.
Clinical trials represent one of the biggest direct-spend components in most pharmaceutical R &D budgets. Failure to enroll adequate numbers of patients is a primary reason why some clinical trials fail. The Cognos Clinical Trial Enrollment Forecasting Blueprint offers the robust forecasting and enrollment analytics pharmaceutical companies need to help ensure adequate patient participation in their clinical trials. The Blueprint maximizes insights into enrollment indicators that can affect the progress of a costly study, and facilitates collaboration between managers, analysts and individual investigator sites to make the necessary adjustments that strike the right balance between cost and performance.
Using out-of-the-box functionality from Cognos 8 Planning and Cognos 8 Business Intelligence (BI) – including dashboards, analytical reports and a pre-configured data model – and encompassing pharmaceutical industry best practices, the Cognos Clinical Trial Enrollment Forecasting Blueprint lets managers:
* Capitalize on an advanced forecasting data model that calculates and presents for analysis a range of metrics, including planned vs. actual enrollment windows, site activations, and screen failure percentages
* Drill into portfolio reports to undertake more detailed analyses of trial enrollment and performance, using up-to-date information from multiple transactional and planning systems
* Forecast the impact of ‘on-the-fly’ changes using ‘What if’ planning and scenario analysis. Changes to one enrollment assumption automatically recalculates all of the impacted data instantly, eliminating the need for off-line number crunching and facilitating faster decision-making
* Easily adjust business rules to best suit current trial management needs and adapt to sudden changes. New assumptions and rules can be quickly configured, tested and pushed out to end-users and analysts without requiring costly developers and complex coding
* View the clinical site hierarchy through a powerful workflow capability that consolidates, in real time, data from the individual investigator-site level up through regions and countries
Available immediately to customers, the Cognos Clinical Trial Enrollment Forecasting Blueprint is the third pharmaceutical solution launched in the past year. Together with the Cognos Clinical Trial Forecasting Blueprint, launched in May 2006, the Blueprints enable customers to seamlessly update financial projections as their enrollment projections evolve, helping them better understand the cost of changes and the dollar effect of enrollment projections. The Cognos Sample Optimization Blueprint, also released in May 2006, rounds out current pharmaceutical offerings.
“Customer-designed or commercial Clinical Trials Management Systems often lack the flexibility and forecasting capability pharmaceutical companies require to model the entire enrollment picture across the development portfolio. Spreadsheets do not offer a viable alternative as they can introduce substantial control risks and do not incorporate enterprise-class functionality such as managed workflow, and the ability to push template changes out to hundreds of users simultaneously,” said Bill Stevens, associate vice president of life sciences at Cognos. “The Cognos Clinical Trial Enrollment Blueprint offers an approach that eliminates typical concerns of data integrity and information silos. Managers gain ‘right-time’ visibility into the enrollment status of their study portfolio, enabling them to define, manage and measure critical performance indicators in an efficient and timely manner.”
Cognos is a recognized leader in delivering performance management solutions for the pharmaceutical industry. Currently, 25 of the top 30 pharmaceutical firms rely on Cognos performance management software, including Novartis, Bayer UK, and Quintiles Transnational. For more information about Cognos solutions for pharmaceuticals and life sciences, please visit www.cognos.com/lifesciences
About Cognos Performance Blueprints:
Cognos offers a full suite of Performance Blueprints to address planning and performance management process areas that directly impact an organization’s ability to create business value. Both functional and industry-specific process areas can now be automated, streamlined and transformed to help organizations quickly create more business value. Developed by the Cognos Innovation Center for Performance Management, the Cognos Performance Blueprints are a key component within the Cognos Performance Management System, which combines technology, best practices, analytical applications and solutions, and a broad network of partners into a single performance management solution. For further information on the Cognos Performance Blueprints see.
Source :
www.cognos.com
